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Objectives: The objective of this study was to attain a better understanding of infectious diseases (ID) physicians’
experience with MDR organism (MDRO) urinary tract infections (UTIs) by means of a survey on disease perception,
diagnostic management and treatment preferences.
Methods: A nine-question survey was developed and distributed to members of the North American Emerging
Infections Network (EIN) in September 2013.
Results: Seven hundred and fourteen out of 1461 EIN members responded to the survey (49%). The responses of
603 responders were studied. Most providers perceived an increase in the incidence of MDRO UTIs over the past
3 years (75% of adult ID responders and 63% of paediatric ID responders). One hundred and thirty-four (22%)
responders prefer intravenous over oral administration of antimicrobials when both are available, 171 (28%)
prefer longer durations of therapy when comparing an MDRO with a susceptible isolate of the same species
and 142 (24%) order a repeat urine culture as ‘proof of cure’ after treating an MDRO UTI. Nevertheless, 530
(88%) responders perceived MDRO UTIs to be of similar severity as non-MDRO UTIs. Fifty-five percent of providers
prescribed fosfomycin for MDRO UTI at least once; the most common prescribing pattern (among a wide
spectrum of approaches) was a single dose (16%).
Conclusions: Future studies on MDRO UTIs should clarify the role of resistance in patient outcomes and the
comparative efficacy of different antimicrobials. Of particular interest is fosfomycin, which is unrelated to
other antibiotic classes and may take a more prominent role in treating MDRO cystitis.
Introduction
Urinary tract infections (UTIs) involving MDR organisms
(MDROs) appear to be increasing.1,2 There is little guidance on
how to best manage MDRO UTIs as many aspects of clinical
care, including when to initiate empirical treatment that covers
MDROs, which antimicrobial to select and the preferable route
of administration, and optimal treatment duration have not
been thoroughly studied.3 The objective of this survey was
to better understand infectious diseases (ID) physicians’
perceptions and behaviours regarding MDRO UTIs using the
CDC-funded, IDSA-hosted Emerging Infections Network (EIN),
a provider-based sentinel network.4 We wanted to determine:
(i) perceived trends of MDRO UTIs; (ii) the perceived severity of
these infections; (iii) preferred antimicrobials, route of adminis-
tration and treatment duration; and (iv) experience with fosfo-
mycin for MDRO UTIs.
Methods
The EIN is an online network established through a Cooperative
Agreement Program Award from the CDC. It consists of physicians who
practice adult and/or paediatric ID and belong to the IDSA and/or the
Pediatric Infectious Diseases Society.
A nine-question survey was developed through collaboration between
EIN leadership (S. E. B. and P. M. P.) and the Division of Infectious Diseases
at Washington University School of Medicine (all other authors). It was dis-
tributed to 1461 EIN members on 9 September 2013 (with two follow-up
reminders for non-responders). For the survey, we defined multidrug
resistance as resistance to at least three antibiotic classes (unless specified
otherwise). The generic ‘UTI’ was intended to encompass lower and upper
UTI. Survey questions 1–3 focused on perceived incidence of MDRO UTIs,
commonly encountered pathogens and microbiological information rou-
tinely available. Questions 4 and 5 addressed diagnostic and management
preferences for MDRO UTIs. Question 6 concerned the perceived likelihood
of clinical resolution with appropriate therapy for specific organisms, and
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questions 7 and 8 concerned the preferences for antimicrobial selection
and treatment duration for specific pathogens. Question 9 was about
the experience of respondents utilizing fosfomycin for the treatment of
MDRO UTIs. Fosfomycin, recommended as first-line therapy in uncompli-
cated UTI, was specifically addressed due to its perceived underutilization
and the potential use in MDRO UTIs. No institutional review board review
was required for this survey.
Results
Overall, 714 (49%) of 1461 EIN members responded to the survey.
In terms of professional experience in ID, responders had
,5 years (18%), 5 –14 years (28%), 15 –24 years (25%) or
≥25 years (28%) of experience. Providers were from all geograph-
ical areas, including the South Atlantic (18%), Pacific (18%), East
North Central (15%) and Mid-Atlantic (14%). The most common
employers were universities/medical schools (40%), followed by
private practice groups (28%), hospitals/clinics (26%), Veteran
Affairs/military (6%) and state government (,1%). The respon-
ders represent adult ID (74%), paediatric ID (22%) or combined
adult/paediatric ID (4%). Significantly more paediatric than
adult ID physicians reported not having managed MDRO UTIs dur-
ing their last 3 years of clinical practice (25% versus 13%;
P¼0.001). We excluded these 111 (16%) ‘non-exposed’ respon-
ders from subsequent analyses and studied the responses of
the remaining 603 providers (the EIN report with full results is
available as Supplementary data at JAC Online).
Most adult and paediatric ID providers perceived an increase in
the incidence of MDRO UTIs over the past 3 years (75% and 63%,
respectively). The most frequently encountered MDROs were
reported to be ESBL-producing Enterobacteriaceae, followed by
VRE, MDR Pseudomonas aeruginosa (MDRPsa), carbapenem-
resistant Enterobacteriaceae (CRE) and carbapenem-resistant
Acinetobacter baumannii (CRAB) (Figure 1). When eliciting the prac-
tices of the local clinical laboratories used by respondents, most
screen for and report VRE (576, 96%), ESBL-producing organisms
(573, 95%) and carbapenemase producers (486, 81%).
Regarding management preferences, 134 (22%) responders
prefer intravenous over oral antibiotic administration when both
are available, 171 (29%) prefer longer treatment durations
when comparing an MDRO with a susceptible isolate of the
same species and 142 (24%) order repeat urine cultures as
‘proof of cure’ after treating MDRO UTIs. To inform treatment
decisions, 568 (94%) providers routinely use urinalysis results in
addition to culture findings; 581 (96%) do not feel compelled to
administer antibiotics if there is low suspicion for infection (i.e.
asymptomatic bacteriuria with MDRO); and 530 (88%) believe
MDRO UTIs are not more severe than non-MDRO infections. The
likelihood of clinical resolution with appropriate therapy was per-
ceived as high for all organisms: susceptible Escherichia coli
(.99%), ESBL producers (99%), VRE (95%), MDRPsa (90%), CRE
(90%) and CRAB (81%). When asked about the preferred duration
of therapy specifically for lower UTI, 65% reported treating
susceptible E. coli for ,7 days, while the majority preferred
7 –14 days for CRE (71%), CRAB (69%), ESBL producers (67%)
and VRE (63%) (Figure 2).
We then solicited the most frequently prescribed antibiotic for
specific uropathogens while explicitly stating an absence of drug
allergies, interacting medications and renal insufficiency. The first
choice for UTIs caused by susceptible E. coli was trimethoprim/
sulfamethoxazole (49%); for ESBL producers and MDRPsa, it was
carbapenems (55% and 41%, respectively); for CRE, it was an
aminoglycoside (28%) or fosfomycin (25%); and for VRE, it was
linezolid (66%). For CRAB UTI, providers primarily selected an
antibiotic ‘other’ (48%) than the ones offered (also including
fluoroquinolones, nitrofurantoin and doxycycline).
Regarding clinical experience with fosfomycin for the treat-
ment of MDRO UTIs, 332 (55%) providers reported prescribing
fosfomycin at least once in this setting. The most common pre-
scribing pattern was a single dose (16%), followed by 3 g once
every 3 days for a total of 9 days (9%), 6 days (7%) or 3 days
(7%). Success rates with fosfomycin for this indication were
thought to be .50% by 282 (88%) responders, .75% by 188
(59%) and .90% by 63 (20%).
Discussion
Infections due to MDROs are on the rise across the globe and pose
significant problems. Yet, we lack treatment guidelines given the
limited evidence from comparative research. This is also true
for UTIs, the most frequent bacterial infection in humans.5
For MDRO UTIs, there are a handful of studies with older drugs
such as fosfomycin6 and newer options such as ceftazidime/
avibactam;7 however, no additional, randomized studies are
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Figure 1. Provider ranking of the most frequently encountered organisms in MDRO UTIs. Inverse median and inverse mean¼ the median and mean
values were inverted 1/x to yield higher values for more important criteria; n¼number of respondents for each category of antibiotic-resistant
organisms shown. ESBL, ESBL-producing Enterobacteriaceae.
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available for guidance. In this survey of ID physicians, responders
perceived the frequency of MDRO UTIs to be increasing and
revealed significant variation in their management approaches.
Interestingly, MDRO UTIs were perceived as similar in severity
to UTIs caused by susceptible organisms. Some data suggest that
the impact of resistance on clinical presentation and outcomes is
not substantial in the case of UTIs.8,9 Consequently, one would
expect treatment preferences to be similar for infections with
resistant or susceptible organisms. However, about one-quarter
of providers reported preferring intravenous over oral medication
(assuming both options are available), choosing longer durations
and obtaining ‘proof of cure’ cultures at the end of treatment.
None of these practices is supported by evidence, but they may
reflect the difficulties physicians encounter when treating
non-UTI MDRO infections (or their anxiety when facing MDROs).
To our knowledge, this mismatch between perceived clinical
impact and preferred management approach has never been
reported in the scientific literature. Currently, it is unknown
whether longer treatment durations are indeed necessary for
MDRO UTIs.
There is limited experience with fosfomycin as a treatment
option for MDRO UTIs in the EIN and, apparently, many never
used it at all. Fosfomycin is unrelated to other antibiotic classes,
retaining its efficacy when organisms have acquired resistance
to more commonly used antimicrobials. In the major treatment
guideline for uncomplicated UTIs, Gupta et al.10 list fosfomycin
as one option and laud it for being well-tolerated and largely
unaffected by resistance problems. Moreover, in two studies, clin-
ical success with fosfomycin for ESBL producers exceeded
90%.6,11 It is unclear, however, how often fosfomycin is utilized
by ID physicians. From our survey, it appears to be regarded as a
second-line treatment option, with fosfomycin resistance testing
not readily available and the ID community uncertain about the
best dosing regimen. While there is an established dose for
uncomplicated cystitis, utility and dosage for complicated UTIs
have not been determined and should be considered ‘off-label’.12
We hypothesize that one barrier to fosfomycin use is the long-
standing quinolone and sulphonamide preference for UTI
treatment. Suboptimal guideline adherence is another potential
cause for low uptake of fosfomycin and is well described.13,14
A major limitation of surveys is that responses are self-reported
perceptions and behaviours; thus, findings may not necessarily
reflect how patients are managed in real life. Our questions did
not differentiate between the selection of empirical versus tar-
geted therapy or consider the effect of cross-resistance in the
organisms involved. The survey addressed UTIs in general and
only focused on lower UTI in one question on treatment duration.
Furthermore, while the sample size of 603 participants was large,
it may not be representative of the North American ID commu-
nity. Findings should not be extrapolated to other geographical
areas with different UTI management strategies.
In conclusion, there is a mismatch between perceived clinical
severity of MDRO UTIs (i.e. no more severe than regular UTIs) and
preferred treatment approach (i.e. longer than regular UTIs and
via the intravenous route). Future studies on MDRO UTIs should
clarify the role of resistance in patient outcomes and the com-
parative efficacy of different antimicrobials and/or durations.
Among the treatment options of particular interest is fosfomycin,
which may take a more prominent role in treating MDRO cystitis.
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